FCM
IMVT icon

Fieldview Capital Management’s Immunovant IMVT Stock Holding History

Fieldview Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286K Buy
+7,424
New +$226K 0.08% 392
2025
Q4 		– Sell
-17,577
Closed -$283K – 555
2025
Q3 		$283K Sell
17,577
-27,524
-61% -$446K 0.05% 336
2025
Q2 		$722K Buy
45,101
+34,322
+318% +$519K 0.11% 215
2025
Q1 		$184K Buy
+10,779
New +$225K 0.03% 387

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fieldview Capital Management's IMVT Position: Q2 2026 in Review

Fieldview Capital Management opened a new position in Immunovant (IMVT) in Q2 2026: 7,424 shares worth $286K. The stake represents 0.08% of the portfolio and ranks #392 among its holdings. This is a return to the name: Fieldview Capital Management previously reported a position in IMVT as recently as Q3 2025.

Fieldview Capital Management first reported a position in IMVT in Q1 2025 and has held it in 4 quarters since. The position peaked at $722K in Q2 2025. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Fieldview Capital Management held 7,424 shares of Immunovant worth $286K as of Q2 2026.
  • Immunovant was a new Fieldview Capital Management position in Q2 2026.
  • Immunovant made up 0.08% of Fieldview Capital Management's portfolio in Q2 2026, its #392 holding.
  • Fieldview Capital Management first reported a position in Immunovant in Q1 2025 and has held it in 4 quarters since.
  • Fieldview Capital Management's Immunovant position peaked at $722K in Q2 2025.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Fieldview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.